These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17451611)
21. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008 [TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Garg N; Tripathy N; Sinha N Cardiol Young; 2011 Dec; 21(6):631-8. PubMed ID: 21729508 [TBL] [Abstract][Full Text] [Related]
23. [Bosenten and sildenafil in the treatment of Eisenmenger syndrome]. Białkowski J Kardiol Pol; 2010 Feb; 68(2):248-9. PubMed ID: 20301040 [No Abstract] [Full Text] [Related]
24. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. Durongpisitkul K; Jakrapanichakul D; Sompradikul S J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984 [TBL] [Abstract][Full Text] [Related]
25. Long-term bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome. Díaz-Caraballo E; González-García AE; Reñones M; Sánchez-Recalde A; García-Río F; Oliver-Ruiz JM Rev Esp Cardiol; 2009 Sep; 62(9):1046-9. PubMed ID: 19712626 [TBL] [Abstract][Full Text] [Related]
28. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Duffels MG; Vis JC; van Loon RL; Berger RM; Hoendermis ES; van Dijk AP; Bouma BJ; Mulder BJ Int J Cardiol; 2009 May; 134(3):378-83. PubMed ID: 18579234 [TBL] [Abstract][Full Text] [Related]
29. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Monfredi O; Griffiths L; Clarke B; Mahadevan VS Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933 [TBL] [Abstract][Full Text] [Related]
31. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Diller GP; Alonso-Gonzalez R; Dimopoulos K; Alvarez-Barredo M; Koo C; Kempny A; Harries C; Parfitt L; Uebing AS; Swan L; Marino PS; Wort SJ; Gatzoulis MA Int J Cardiol; 2013 Aug; 167(3):840-7. PubMed ID: 22390966 [TBL] [Abstract][Full Text] [Related]
32. Effect of bosentan therapy on ventricular and atrial function in adults with Eisenmenger syndrome. A prospective, multicenter study using conventional and Speckle tracking echocardiography. Abd El Rahman MY; Rentzsch A; Scherber P; Mebus S; Miera O; Balling G; Böttler P; Dubowy KO; Farahwaschy B; Hager A; Kreuder J; Peters B; Berger F; Schulze-Neick I; Abdul-Khaliq H Clin Res Cardiol; 2014 Sep; 103(9):701-10. PubMed ID: 24682249 [TBL] [Abstract][Full Text] [Related]
33. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007 [TBL] [Abstract][Full Text] [Related]
34. Eisenmenger syndrome in the adult--experience with new drugs for the treatment of pulmonary hypertension. Agapito AF; Sousa L; Oliveira JA; Feliciano J; Cacela D; Quininha J Rev Port Cardiol; 2005 Mar; 24(3):421-31. PubMed ID: 15929625 [TBL] [Abstract][Full Text] [Related]
35. Eisenmenger syndrome and juvenile rheumatoid arthritis--a case of double diagnosis. Ozdemir O; Agras PI; Hizli S; Guveloglu M; Kabakus N Kardiol Pol; 2009 Dec; 67(12):1377-80. PubMed ID: 20054770 [TBL] [Abstract][Full Text] [Related]
36. Response to bosentan in children with pulmonary hypertension. Maiya S; Hislop AA; Flynn Y; Haworth SG Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850 [TBL] [Abstract][Full Text] [Related]
37. Bosentan therapy for pulmonary arterial hypertension. Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289 [TBL] [Abstract][Full Text] [Related]
38. Initial experience with Bosentan therapy in patients with the Eisenmenger syndrome: Tetralogy of Fallot? Beghetti M; Trindade PT; Friedli B Am J Cardiol; 2005 Feb; 95(3):435-6; author reply 436. PubMed ID: 15670566 [No Abstract] [Full Text] [Related]
39. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Schulze-Neick I; Gilbert N; Ewert R; Witt C; Gruenig E; Enke B; Borst MM; Lange PE; Hoeper MM Am Heart J; 2005 Oct; 150(4):716. PubMed ID: 16209972 [TBL] [Abstract][Full Text] [Related]
40. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]